Sector Expert: William Gregozeski
William Gregozeski has spent more than 10 years working as an industry-agnostic equity analyst covering securities listed around the world. Gregozeski currently manages the sellside equity research department and oversees U.S. client relationships at Mont Blanc Capital Management, a Zurich-based investment firm. Previous work includes writing sellside research on U.S.-listed small-cap companies at Gar Wood Securities, a Chicago-based broker dealer, and researching the cleantech industry in the U.S. and small-cap China-based companies at Capstone Investments, a San Diego-based broker dealer. Gregozeski is a CFA charterholder, has obtained a bachelor's degree in finance and a master's degree in business administration from Marquette University, and currently holds FINRA Series 7, 24, 66, 79, 86, and 87 licenses.
Adventurous investors have long sought out micro-cap stocks, attracted by the profit potential of starting on the bottom floor and rocketing toward blue sky. Biotechnology can add even more power to the upside possibilities of micro caps, especially now that pharma is starved for new products and will pay well for solid ideas. Managing partner William Gregozeski of Mont Blanc Capital Management has focused on very small, unnoticed stocks for most of his career and has pegged two undiscovered biotechs that could break out to big-time valuations. In this interview with The Life Sciences Report, Gregozeski elaborates on the stories behind these two investment opportunities.
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity."
The Life Sciences Report Interview with William Gregozeski
"BTI's BT2111 shows significant advantages over Herceptin."
William Gregozeski, Mont Blanc Capital Management